Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That ...

Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

While the issues with Garrard County Distilling, Luca Mariano Distillery, Whiskey House of Kentucky and Brown-Forman vary, ...

People who use popular diabetes drugs called GLP-1 receptor agonists may be at  increased risk for a serious eye disease, a ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...